News

The trial met its objectives and identified a Phase 2 dose regimen. Celiac disease is an immune-mediated gastrointestinal disease caused by dietary gluten predominantly in individuals who carry

This financing was led by Topspin Biotech Fund and a group of investors with Euclidean Capital, with participation from existing investors InterWest Partners, OrbiMed Advisors, and Osage University

The phase 3 ADAPT clinical trial, which is assessing rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of metastatic renal cell carcinoma (mRCC), has been concluded as futility

Currently, Inotuzumab ozogamicin is being assessed for treatment of adult patients with acute lymphoblastic leukemia (ALL) both in relapsed and refractory B-cell precursor forms. The drug will now

AGS-v is intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability

Under the agreement, Abzena will manufacture Magacizumab, an antibody created using the ‘Abzena inside’ Composite Human Antibody technology. Under earlier agreements with UCL, Abzena conducted the antibody humanization and

Alecensa, which is an oral medicine produced at Chugai Kamakura, is being developed for people with NSCLC whose tumours are identified as ALK-positive. The European Commission has granted approval

Savolitinib is a highly selective and potent oral c-Met inhibitor with global first-in-class potential.  The first drug dose was administered on February 10, 2017. This Phase II study

Modus Therapeutics is currently recruiting patients in Europe, the Middle East and Caribbean in an ongoing Phase II clinical study with sevuparin for SCD. In the second half